Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 23 h ago

TENAX THERAPEUTICS, INC.: ADAR1 Capital Management, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 17 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

ADAR1 Capital Management, LLC amended its Schedule 13G stake filing for Tenax Therapeutics, Inc., according to SEC accession 0001104659-26-128734. The filing updates the investment firm's previously reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed when a passive investor's ownership crosses a 5% threshold or changes materially, making the disclosure a signal of shifting institutional interest in the small-cap name. Investors will watch for further 13G or 13D filings to gauge whether ADAR1's position is building or being trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

ADAR1 Capital Management, LLC, TENAX THERAPEUTICS, INC.